Skip to main content

Mecanometabolismo de la insuficiencia cardiaca asociada a la edad - CardioAging

PLEC2022-009235

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i en Líneas Estratégicas
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Overexpression of wild-type TMEM43 improves cardiac function in arrhythmogenic right ventricular cardiomyopathy type 5

  • Lalaguna, Laura
  • Arévalo-Núñez De Arenas, María
  • López-Olañeta, Marina
  • Villalba-Orero, María
  • Jiménez-Riobóo, Rafael J.
  • Gómez-Gaviro, María Victoria
  • Isern, Joan
  • Muñoz Cánoves, Pura, 1962-
  • Byrne, Barry J.
  • Ochoa, Juan Pablo
  • García-Pavía, Pablo
  • Lara-Pezzi, Enrique
BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy type 5 (ARVC5) is the most aggressive type of ARVC, caused by a fully penetrant missense mutation (p.S358L) in TMEM43 (transmembrane protein 43). Pathologically, the disease is characterized by dilation of the cardiac chambers and fibrofatty replacement of the myocardium, which results in heart failure and sudden cardiac death. Current therapeutic options are limited, and no specific therapies targeting the primary cause of the disease have been proposed. METHODS: We investigated whether overexpression of wild-type (WT) TMEM43 could overcome the detrimental effects of the mutant form. We used transgenic mouse models overexpressing either WT or mutant (S358L) TMEM43 to generate a double transgenic mouse line overexpressing both forms of the protein. In addition, we explored if systemic delivery of a codon-optimized self-complementary adeno-associated virus bearing WT-TMEM43 could improve disease progression assessed by ECG and echocardiography. RESULTS: Double transgenic mice overexpressing both WT and mutant TMEM43 forms showed delayed ARVC5 onset, improved cardiac contraction, and reduced ECG abnormalities compared with mice expressing S358L-TMEM43. In addition, cardiomyocyte death and myocardial fibrosis were reduced, with an overall increase in survival. Finally, we demonstrated that a single systemic administration of an adeno-associated virus carrying codon-optimized WT-TMEM43 prevents ventricular dysfunction and ECG abnormalities induced by S358L-TMEM43. CONCLUSIONS: Overexpression of WT-TMEM43 improves the pathological phenotype in a mouse model of ARVC5. Adeno-associated virus-mediated delivery of WT-TMEM43 offers a promising and specific therapy for patients suffering from this highly lethal disease., This study was funded by the Pathfinder Cardiogenomics program of the European Innovation Council of the European Union (DCM-NEXT project; project number: 101115416) and grants PID2021-124629OB-I00, TED2021-129774BC22, and PLEC2022-009235 funded by the Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033), the European Union's NextGenerationEU/PRTR (Plan de Recuperación, Transformación y Resiliencia de España), and Fondo Europeo de Desarrollo Regional (FEDER) to E. Lara-Pezzi. The Centro Nacional de Investigaciones Cardiovasculares (CNIC) is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia, Innovación y Universidades (MICIU) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIU/AEI/10.13039/501100011033).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Modeling heart flow dynamics using numerical simulations to identify the vortex ring: A practical guide

  • Lazpita, Eneko
  • Garicano-Mena, Jesús
  • Le clainche, Soledad
  • Mares-Bou, Andrea|||0000-0002-3720-6710
  • Quintero-Igeño, Pedro-Manuel|||0000-0003-4373-2079
[EN] In this study, we present a comprehensive numerical analysis of blood flow within human left ventricle models, with particular emphasis on optimizing simulation conditions to enhance the realism and computational efficiency of heart flow dynamics. The objective is to determine the most effective mesh configurations, flow conditions, and boundary settings necessary for accurately capturing the formation and behavior of the vortex ring¿a pivotal element in ventricular flow dynamics. Utilizing a computational fluid mechanics approach, we review the influence of both idealized and patient-specific geometries on simulation outcomes. It is imperative to consider the necessity of dynamic wall motion and the precise calibration of inlet and outlet boundary conditions, which must be designed to mimic physiological conditions as accurately as possible. These factors are of paramount importance in achieving a balance between computational resource demands and the fidelity of the simulations, thereby providing valuable insights for future cardiovascular modeling efforts. Tutorials explaining details of the simulations and the codes used are included in ModelFLOWs-app website, The authors acknowledge the grants TED2021-129774B-C21 and PLEC2022-009235 funded by MCIN/AEI/10.13039/501100011033 and by the European Union NextGenerationEU /PRTR and the grant PID2023-147790OB-I00 funded by MCIU/AEI/10.13039/ 501100011033/FEDER, UE. The authors gratefully acknowledge the Universidad Politécnica de Madrid (www.upm.es) for providing computing resources on Magerit Supercomputer. P.Q. would like to acknowledge the support of DIDIMO, Grant PLEC2021-007614 funded by MCIN/AEI/10.13039/501100011033 and, as appropriate, by the ERDF A way of making Europe , and the European Union NextGenerationEU/PRTR
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

MCJ: A mitochondrial target for cardiac intervention in pulmonary hypertension

  • Santamans, Ayelén M.
  • Cicuéndez, Beatriz
  • Mora, Alfonso
  • Villalba-Orero, María
  • Rajlic, Sanela
  • Crespo, María
  • Vo, Paula
  • Jerome, Madison
  • Macías, Álvaro
  • López, Juan Antonio
  • Leiva, Magdalena
  • Rocha, Susana F.
  • León, Marta
  • Rodríguez, Elena
  • Leiva-Vega, Luis
  • Pintor-Chocano, Aránzazu
  • García-Lunar, Inés
  • García-Álvarez, Ana
  • Hernansanz-Agustín, Pablo
  • Peinado, Víctor
  • Barberà, Joan Albert
  • Ibáñez, Borja
  • Vázquez, Jesús
  • Spinelli, Jessica B.
  • Daiber, Andreas
  • Oliver, Eduardo
  • Sabio, Guadalupe
17 p.-6 fig.-2 tab., Pulmonary hypertension (PH) can affect both pulmonary arterial tree and cardiac function, often leading to right heart failure and death. Despite the urgency, the lack of understanding has limited the development of effective cardiac therapeutic strategies. Our research reveals that MCJ modulates mitochondrial response to chronic hypoxia. MCJ levels elevate under hypoxic conditions, as in lungs of patients affected by COPD, mice exposed to hypoxia, and myocardium from pigs subjected to right ventricular (RV) overload. The absence of MCJ preserves RV function, safeguarding against both cardiac and lung remodeling induced by chronic hypoxia. Cardiac-specific silencing is enough to protect against cardiac dysfunction despite the adverse pulmonary remodeling. Mechanistically, the absence of MCJ triggers a protective preconditioning state mediated by the ROS/mTOR/HIF-1α axis. As a result, it preserves RV systolic function following hypoxia exposure. These discoveries provide a potential avenue to alleviate chronic hypoxia-induced PH, highlighting MCJ as a promising target against this condition., This study was financially supported by the following: Interacciones celulares y sistémicas entre el cáncer y la señalización metabólica, exp: RED2022-134397-T (G.S.); Proyectos I+D+i 2019 - Proyecto MINECO-PID2019-104399RB-I00 financiado por MCIN/AEI/10.13039/501100011033 (G.S.); Proyectos de I+D de Generación de Conocimiento 2018 funded by Ministerio de Economía y Competitividad (PGC2018-097019-B-I00) (G.S.); PreMed-Exp: PMP21/00057 (G.S.); Fundación Jesús Serra (G.S.); EFSD/Lilly European Diabetes Research Programme (G.S.); BBVA Foundation Leonardo Grants program for Researchers and Cultural Creators (Investigadores-BBVA-2017) (G.S.); Fundación AECC PROYE19047SABI (G.S.); Comunidad de Madrid IMMUNOTHERCAN-CM S2010/BMD-2326 (G.S.); FPI Severo Ochoa CNIC program (BES-2016-077635) (A.M.S.); JDC-2020 Incorporación (IJC2020-042679-I) (P.H.-A.); Fondo Europeo de Desarrollo Regional (FEDER) Instituto de Salud Carlos III-Fondo de Investigación Sanitaria PI17/00995 (A.G.-Á.); Fondo Europeo de Desarrollo Regional (FEDER) Instituto de Salud Carlos III-Fondo de Investigación Sanitaria (PI20/00742) (A.G.-Á.); Intensificación AES2019 (AGA); Fundación “La Caixa”: Macromoleculopathies (LCF/PR/HR19/52160013) of the call HEALTH RESEARCH 2018 (Á.Ma.); Programa de Atracción de Talento (2017-T1/BMD-5185) funded by Comunidad de Madrid (E.O.); Ramón y Cajal grant (RYC2020-028884-I) funded by MCIN/AEI/10.13039/501100011033 and by “ESF Investing in your future” (E.O.); Juan de la Cierva Incorporación Grant (IJCI-2016-27698) (M.V.O.); Worcester Foundation for Biomedical Research (J.B.S.); Boehringer Ingelheim Foundation (collaborative research group “Novel and neglected cardiovascular risk factors: molecular mechanisms and therapeutics”) (A.D.); Foundation Heart of Mainz (A.D.); DZHK (German Center for Cardiovascular Research), Partner Site Rhine-Main, Mainz, Germany (A.D.); Ministerio de Ciencia e Innovación (PGC2018-097019-B-I00, PID2021-122348NB-I00, PLEC2022-009235, and PLEC2022-009298) (J.V.); Fundación “La Caixa” (HR17-00247 and HR22-00253) (J.V.); Carlos III Institute of Health-Fondo de Investigación Sanitaria grant PRB3 (PT17/0019/0003- ISCIII-SGEFI/ERDF, ProteoRed) (J.V.); and Comunidad de Madrid (IMMUNO-VAR, P2022/BMD-7333) (J.V.). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN), and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Immune synapse formation promotes lipid peroxidation and MHC-I upregulation in licensed dendritic cells for efficient priming of CD8+ T cells

  • Calzada-Fraile, Diego
  • Iborra, Salvador
  • Ramírez-Huesca, Marta
  • Jorge, Inmaculada
  • Dotta, Enrico
  • Hernández-García, Elena
  • Martín-Cófreces, Noa Beatriz
  • Nistal-Villán, Estanislao
  • Veiga, Esteban
  • Vázquez, Jesús
  • Pasqual, Giulia
  • Sánchez-Madrid, Francisco
Antigen cognate dendritic cell (DC)-T cell synaptic interactions drive activation of T cells and instruct DCs. Upon receiving CD4+ T cell help, post-synaptic DCs (psDCs) are licensed to generate CD8+ T cell responses. However, the cellular and molecular mechanisms that enable psDCs licensing remain unclear. Here, we describe that antigen presentation induces an upregulation of MHC-I protein molecules and increased lipid peroxidation on psDCs in vitro and in vivo. We also show that these events mediate DC licensing. In addition, psDC adoptive transfer enhances pathogen-specific CD8+ T responses and protects mice from infection in a CD8+ T cell-dependent manner. Conversely, depletion of psDCs in vivo abrogates antigen-specific CD8+ T cell responses during immunization. Together, our data show that psDCs enable CD8+ T cell responses in vivo during vaccination and reveal crucial molecular events underlying psDC licensing., This study was supported by the Spanish Ministry of Science and Innovation (grants PID2020-120412RB-I00, PDC2021-121797-I00, PGC2018-097019-BI00, PID2021-122348NB-I00, PLEC2022-009235, PLEC2022-009298, PID2021-125415OB-I00, and PID2019-105761RB-I00); Comunidad de Madrid (INTEGRAMUNE, P2022/BMD7209 and IMMUNO-VAR, P2022/BMD-7333); Ramón Areces Foundation “Ciencias de la Vida y la Salud” (XIX Concurso-2018); “la Caixa” Banking Foundation (grants HR17-00016, HR17-00247, and HR22-00253); ProteoRed from Instituto de Salud Carlos III (PT17/0019/0003- ISCIII-SGEFI / ERDF); CIBER Cardiovascular (CB16/11/00272, CB16/11/00277); Agencia Estatal de Investigación (AEI); Fondo de Investigación Sanitaria del Instituto de Salud Carlos III; co-funding by Fondo Europeo de Desarrollo Regional (FEDER); and European Research Council Starting Grant SYNVIVO 853179. D.C.-F. is supported by an INPhINIT Retaining Fellowship from “la Caixa” Foundation (LCF/BQ/DR19/11740010). S.I. is supported by a RYC-2016-19463 fellowship. E.H. is supported by an FPI fellowship (PRE2019-087509). We thank Miguel Vicente-Manzanares for critically reading the manuscript. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A New GlyT2 Variant Associated with Hyperekplexia

  • Sarmiento-Jiménez, Jorge
  • Felipe, Raquel
  • Núñez, Enrique
  • Ferrando-Muñoz, Alejandro
  • Benito-Muñoz, Cristina
  • Gago, Federico
  • Vázquez, Jesús
  • Camafeita, Emilio
  • Clement, Emma
  • Wilson, Brian
  • López-Corcuera, Beatriz
This article belongs to the Special Issue Genetic and Genomic Diagnostics for Rare Diseases., [Data Availability Statement] The datasets generated and/or analyzed during the current study are not publicly available due to individual privacy, but some data are available from the corresponding author on reasonable request. Proteomic data are available via ProteomeXchange with the identifier PXD061845., Hyperekplexia (OMIM 149400), a sensorimotor syndrome of perinatal clinical relevance, causes newborns to display an energic startle reflex in response to certain trivial stimuli. This condition can be lethal due to apnea episodes. The disease is caused by a blockade of glycinergic neurotransmission. Glycinergic interneurons preserve their identity by the activity of the surface glycine transporter GlyT2, which supplies glycine to presynaptic terminals to maintain glycine content in synaptic vesicles. Loss-of-function mutations in the GlyT2 gene (SLC6A5) cause a presynaptic form of human hyperekplexia. Here, we describe a new GlyT2 variant found in an infantile patient diagnosed with hyperekplexia. A missense mutation in the open reading frame of the GlyT2 gene inherited in homozygosity caused the substitution G449E in a residue highly conserved across the phylogenetic scale. The sequences of the glycine receptor genes GLRA1 and GLRB did not show abnormalities. We expressed the recombinant GlyT2 variant in heterologous cells and analyzed its pathogenic mechanism. The transporter was totally inactive, behaving as a bona fide loss-of-function mutant. Furthermore, the mutation promoted the abnormal insertion of the protein into the membrane, leading to its large incorporation into lipid rafts. However, there was no apparent alteration of wild-type trafficking upon mutant coexpression, as the mutant was prematurely degraded from the endoplasmic reticulum. Rescue with chemical chaperones was not possible for this mutant. Proteomics demonstrated that the expression of the mutant induced the unfolded protein response and interfered with raft-dependent processes. Therefore, the new variant causes a loss of function regarding GlyT2 activity but a gain of function as a cell proteostasis disturber., This research was funded by the Ministerio de Ciencia e Innovación (MCIN) MCIN/AEI/10.13039/501100011033, grant numbers PID2020-119399RB-I00 and PID2023-150608OB-I00 to B.L.-C.; the Fundación Ramón Areces, grant number CIVP20A6612 to B.L.-C.; and an institutional grant from the Fundación Ramón Areces to the CBM Severo Ochoa. The work at the CNIC was supported by grant EQC2021-007053-P funded by MCIN/AEI/10.13039/501100011033 and by NextGenerationEU/PRTR; grant PID2021-122348NB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”; grant PLEC2022-009298 funded by MCIN/AEI/10.13039/501100011033 and by “European Union NextGenerationEU/PRTR”; grant PLEC2022-009235 funded by MCIN/AEI/10.13039/501100011033 and by “European Union NextGenerationEU/PRTR”; grant S2022/BMD-7333-CM (INMUNOVAR-CM) funded by Comunidad de Madrid; and “la Caixa” Foundation under the project code LCF/PR/HR22/52420019 to J.V. The CBMSO is a Severo Ochoa Center of Excellence (CEX2021-001154-S). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033). Work at the University of Alcalá was supported by the MCIN grant PID2022-136307OB-C22/AEI/10.13039/501100011033., With funding form the Spanish government through the "Severa Ochoa Centre of Excellence" accreditation (CEX2021-001154-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cerebrospinal fluid lipoprotein-mediated cholesterol delivery to neurons is impaired in Alzheimer's disease and involves APOE4

  • Borràs, Carla
  • Canyelles, Marina
  • Santos, David
  • Rotllan, Noemí
  • Núñez, Estefanía
  • Vázquez, Jesús
  • Maspoch, Daniel
  • Cano-Sarabia, Mary
  • Zhao, Qi
  • Carmona, María
  • Sirisi, Sònia
  • Lleó, Alberto
  • Fortea, Juan
  • Alcolea, Daniel
  • Blanco-Vaca, Francisco
  • Escolà, Joan Carles
  • Tondo, Mireia
In the central nervous system, apolipoprotein (APO)E-containing lipoprotein particles mediate the transport of glial-derived cholesterol to neurons, which is essential for neuronal membrane remodeling and maintenance of the myelin sheath. We aimed to examine cholesterol transport via lipoprotein particles in cerebrospinal fluid (CSF) of Alzheimer's disease (AD) patients compared to control individuals. Additionally, we explored the ability of reconstituted HDL containing different APOE isoforms to regulate cholesterol transport. We evaluated the capacity of CSF lipoprotein particles to facilitate radiolabeled unesterified cholesterol efflux from A172 human glioblastoma astrocytes and to deliver cholesterol to SH-SY5Y human neuronal cells. The CSF lipoprotein proteome was analyzed by LC-MS/MS. Reconstituted HDL nanoparticles were prepared by combining phospholipids and cholesterol with human APOE3 or APOE4, followed by radiolabeling with unesterified cholesterol. Our results showed that cholesterol efflux from astrocytes to CSF were similar between AD patients and controls, both under baseline conditions and after activation of ABCA1 and ABCG1. However, CSF lipoprotein-mediated neuronal cholesterol uptake was significantly reduced in the AD group. LC-MS/MS analysis identified 239 proteins associated with CSF lipoproteins in both groups, with no major alterations in proteins linked to cholesterol metabolism. However, 27 proteins involved in noncholesterol-related processes were differentially expressed. Notably, synthetic reconstituted HDL particles containing APOE4 exhibited reduced capacity to deliver cholesterol to neurons compared to those with APOE3. These findings indicate that CSF lipoproteins from patients with AD demonstrate impaired cholesterol delivery to neurons. Our study highlights APOE4 as a critical contributor to abnormal neuronal cholesterol uptake in AD pathophysiology., This work was partly funded by the Instituto de Salud Carlos III and FEDER "Una manera de hacer Europa" grants PI2100140 (to F. B.-V. and M. T.), PI2300232 (to M. C. and J. E-G.), PI18/0035 and PI22/00758 (to M. C.-I.), JR22/00003 (to M. C.), INT21/00073, PI20/01473, and PI23/01786 (to J. F.) and the Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas Program 1, partly jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, Una Manera de Hacer Europa, and cofunded by the European Regional Development Fund/European Social Fund (ERDF/ESF), “A way to make Europe”/“Investing in your future”. This work was also supported by the National Institutes of Health grants (R01 AG056850; R21 AG056974, R01 AG061566, R01 AG081394, and R61AG066543 to J. F. It was also supported by Fundación Tatiana Pérez de Guzmán el Bueno (IIBSP-DOW-2020-151 to J. F.) and Horizon 2020–Research and Innovation Framework Programme from the European Union (H2020-SC1-BHC-2018-2020 to J. F.). CIBERDEM, CIBERCV, and CIBERNED are Instituto de Salud Carlos III projects. C. B. was funded with a Formación de Profesorado Universitario grant FPU20/07440 from Ministerio de Universidades. Q. Z. was supported by the State Scholarship Fund from the China Scholarship Council (Grant No. 202406170068). N. R. was funded by Agencia Estatal de Investigación (AEI/10.13039/501100011033) within the Subprograma Ramón y Cajal (RYC-201722879). ICN2 is supported by the Severo Ochoa Centers of Excellence program, Grant CEX2021-001214-S, funded by MCIN/AEI/10.13039.501100011033. This study was supported by competitive grants PID2021-122348NB-I00 funded by MICIU/AEI/10.13039/501100011033 (to J. V.) and by “ERDF A way of making Europe”, PLEC2022-009298, PLEC2022-009235, and EQC2021-007053-P funded by MICIU/AEI/10.13039/501100011033 (to J. V.) and by “European Union NextGenerationEU/PRTR”, S2022/BMD-7333-CM (INMUNOVAR-CM) funded by Comunidad de Madrid (to J. V.), and LCF/PR/HR22/52420019 funded by “la Caixa” Foundation (to J. V.)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001214-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Pleiotropic impact of the loss of complex II in the organization of the respiratory chain and the mitochondrial ultrastructure

  • Esteban-Amo, María J.
  • Acín-Pérez, Rebeca
  • Fernandez-Martinez, Silvia
  • Calvo, Enrique
  • Vázquez, Jesús
  • Enríquez, José Antonio
  • Fuente, Miguel A. de la
  • Simarro-Grande, María
Succinate dehydrogenase (SDH, mitochondrial complex II) connects the tricarboxylic acid cycle and oxidative phosphorylation, and its dysfunction is associated with a broad spectrum of human diseases. It comprises a catalytic SDHA subunit and the electron-transferring SDHB subunit, which transfers electrons to the membrane-embedded SDHC/SDHD module where ubiquinone reduction occurs. Recessive defects in SDHA cause early-onset mitochondrial and neurodegenerative disorders, whereas heterozygous mutations in SDHB predispose to tumor development. A distinctive feature of SDHB deficiency is the accumulation of a stable assembly intermediate (CII-low) containing flavinated SDHA, whose functional relevance remains largely unexplored. Despite extensive characterization of SDH-related metabolic alterations, its direct impact on mitochondrial respiration and respiratory chain architecture has remained insufficiently defined. To address this critical gap, we established human cellular models deficient in either SDHA or SDHB, enabling discrimination between complete loss of complex II and conditions marked by CII-low accumulation. We found that CII-low lacked uncoupled activity despite containing flavinated SDHA. In both models, the loss of complex II activity caused severe impairment of mitochondrial respiration and ATP production. These changes were accompanied by marked remodeling of the respiratory chain, with complex I being the most consistently affected complex, as shown by BN-PAGE and proteomic analyses. At the organelle level, SDH deficiency induced mitochondrial abnormalities, including reduced cristae density. The similarity between the two knockout models indicates that the presence of CII-low does not make a major contribution to the observed phenotypes. These findings indicate that SDH deficiency contributes to disease through disruption of mitochondrial respiratory chain organization and ultrastructure., MS and MAF acknowledge grant PID2023-150506OB-I00 funded by MICIU and VA172P20 funded by Junta de Castilla y León. JV acknowledges grants PID2021-122348NB-I00 and PID2024-155650NB-I00 funded by MICIU and by “ERDF A way of making Europe”, PLEC2022-009298, PLEC2022-009235 and EQC2021-007053-P funded by MICIU and by “European Union NextGenerationEU/ PRTR”, S2022/BMD-7333-CM (INMUNOVAR-CM) funded by Comunidad de Madrid and LCF/PR/HR22/52420019 funded by ‘la Caixa’ Foundation. MJEA was supported by a predoctoral contract from the University of Valladolid., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Overexpression of wild-type TMEM43 improves cardiac function in arrhythmogenic right ventricular cardiomyopathy type 5

  • Lalaguna, Laura
  • Arévalo-Núñez De Arenas, María
  • López-Olañeta, Marina
  • Villalba-Orero, María
  • Jiménez-Riobóo, Rafael J.
  • Gómez-Gaviro, María Victoria
  • Isern, Joan
  • Muñoz Cánoves, Pura, 1962-
  • Byrne, Barry J.
  • Ochoa, Juan Pablo
  • García-Pavía, Pablo
  • Lara-Pezzi, Enrique
BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy type 5 (ARVC5) is the most aggressive type of ARVC, caused by a fully penetrant missense mutation (p.S358L) in TMEM43 (transmembrane protein 43). Pathologically, the disease is characterized by dilation of the cardiac chambers and fibrofatty replacement of the myocardium, which results in heart failure and sudden cardiac death. Current therapeutic options are limited, and no specific therapies targeting the primary cause of the disease have been proposed. METHODS: We investigated whether overexpression of wild-type (WT) TMEM43 could overcome the detrimental effects of the mutant form. We used transgenic mouse models overexpressing either WT or mutant (S358L) TMEM43 to generate a double transgenic mouse line overexpressing both forms of the protein. In addition, we explored if systemic delivery of a codon-optimized self-complementary adeno-associated virus bearing WT-TMEM43 could improve disease progression assessed by ECG and echocardiography. RESULTS: Double transgenic mice overexpressing both WT and mutant TMEM43 forms showed delayed ARVC5 onset, improved cardiac contraction, and reduced ECG abnormalities compared with mice expressing S358L-TMEM43. In addition, cardiomyocyte death and myocardial fibrosis were reduced, with an overall increase in survival. Finally, we demonstrated that a single systemic administration of an adeno-associated virus carrying codon-optimized WT-TMEM43 prevents ventricular dysfunction and ECG abnormalities induced by S358L-TMEM43. CONCLUSIONS: Overexpression of WT-TMEM43 improves the pathological phenotype in a mouse model of ARVC5. Adeno-associated virus-mediated delivery of WT-TMEM43 offers a promising and specific therapy for patients suffering from this highly lethal disease., This study was funded by the Pathfinder Cardiogenomics program of the European Innovation Council of the European Union (DCM-NEXT project; project number: 101115416) and grants PID2021-124629OB-I00, TED2021-129774BC22, and PLEC2022-009235 funded by the Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033), the European Union's NextGenerationEU/PRTR (Plan de Recuperación, Transformación y Resiliencia de España), and Fondo Europeo de Desarrollo Regional (FEDER) to E. Lara-Pezzi. The Centro Nacional de Investigaciones Cardiovasculares (CNIC) is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia, Innovación y Universidades (MICIU) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIU/AEI/10.13039/501100011033).